The study of the antigenic and sialic acid binding sites on the hemagglutinin molecule of influenza virus by recombinant DNA technique.
The study of the antigenic and sialic acid binding sites on the hemagglutinin molecule of influenza virus by recombinant DNA technique.
批准号:
60480170
负责人:
NAKAJIMA Katsuhisa
金额:
$4.29万
依托单位国家:
日本
项目类别:
Grant-in-Aid for General Scientific Research (B)
财政年份:
1985
资助国家:
日本
项目状态:
已结题
起止时间:
1985 至 1986
中文摘要
将B-1-23病毒Hal区190位氨基酸发生改变的变异株A/USSR/90/77(A/USSR/77)(H1N1)的HA基因全长克隆到表达载体SV40中。重组病毒感染的CV-1细胞上表达的HA蛋白与感染B-1-23病毒的细胞上表达的HA蛋白的吸血或融合活性无明显差异。用5株抗A/USSR/77病毒HA的单抗检测表达的HA蛋白的抗原性。除mAb264外,其余单抗均可与HA蛋白反应。为了确定表位264的区域,我们制备了7个经定点突变修饰的HA cDNA,并将其克隆到SV40表达载体(SVHA)中。Raymond等人的核苷酸序列分析表明,A/BASIS/11/78的变异氨基酸残基为219(Lys)和227(Glu),A/Lackland/3/78的189(Lys)和225(Asp)可能包含在表位265区域。我们的结果表明,在这些氨基酸中,有190和219个残基,可能还有189个残基,涉及到表位264,但不包括残基225和227。
英文摘要
Full-length cDNA of HA gene derived from B-1-23 virus, a variant of A/USSR/90/77 (A/USSR/77) (HlNl) which had been selected with monoclonal antibody (mAb) 264 and contained an amino acid change at position 190 of the HAl region, was cloned into the SV40 expression vector. Hemabsorbing or fusion activities of the HA protein expressed on CV-1 cells infected with the recombinant virus were indistinguishable from those of the authentic HA protein on B-1-23 virus infected cells. The antigenicity of the expressed HA protein was examined with five monoclonal antibodies to the HA of A/USSR/77 virus. The HA protein reacted with all mAbs except for mAb264. To define the area of epitope 264, we prepared seven HA cDNAs modified by site specific mutagenesis, and cloned them into the SV40 expression vector (SVHA). Raymond et al showed that changed amino acid residues 219 (lys) and 227 (Glu) in A/Brazil/11/78, and 189 (Lys) and 225 (Asp) in A/Lackland/3/78 were presumaly included in the area of epitope 265 by the nucleotide sequence analysis. Of those amino acids, our results shows it is the residues 190 and 219 and possibly residue 189 that are involved in the epitope 264, but neither the residue 225 nor 227.
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Eri Nobusawa, Katsuhisa Nakajima and Setsuko Nakajima: "Expression of hemagglutinin gene" Vaccine. 3. 172-174 (1985)
Eri Nobusawa、Katsuhisa Nakajima 和 Settsuko Nakajima:“血凝素基因的表达”疫苗。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Eri Nobusawa;Katsuhisa Nakajima;Setsuko Nakajima: Virology.
Eri Nobusawa;Katsuhisa Nakajima;Settsuko Nakajima:病毒学。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Eri Nobusawa, Katsuhisa Nakajima and Setsuko Nakajima: "Determination of the epitope 264 on the hemagglutinin molecule of influenza HlNl virus by site specific mutagenesis." Virology. in press.
Eri Nobusawa、Katsuhisa Nakajima 和 Setsuko Nakajima:“通过位点特异性诱变测定流感 H1N1 病毒血凝素分子上的表位 264”。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Eri Nobusawa;Katsuhisa Nakajima;Setsuko Nakajima: Vaccine. 3. 172-174 (1985)
信泽绘里;中岛克久;中岛节子:疫苗。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
The analysis of the restriction of amino acid substitution on the hemagglutinin molecule of influenza A virus
-
批准号:14370104
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$8.77万
-
财政年份:2002
-
负责人:NAKAJIMA Katsuhisa
-
依托单位:
molecular basis for the virion formation of influenza virus
-
批准号:10470082
-
项目类别:Grant-in-Aid for Scientific Research (B).
-
资助金额:$8.45万
-
财政年份:1998
-
负责人:NAKAJIMA Katsuhisa
-
依托单位:
The study on the molecular basis for neurovirulence of influenza virus.
-
批准号:08457099
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$4.99万
-
财政年份:1996
-
负责人:NAKAJIMA Katsuhisa
-
依托单位:
The study of the production of human antibody in vitro expression system and recognition of epitope on the HA protein by human immune system.
-
批准号:04454202
-
项目类别:Grant-in-Aid for General Scientific Research (B)
-
资助金额:$4.29万
-
财政年份:1992
-
负责人:NAKAJIMA Katsuhisa
-
依托单位:
The Analysis of the Structure of Receptor Binding Site of Hemagglutin in Molecule of Influenza A Virus and of the Characteristics of Receptor.
-
批准号:63480157
-
项目类别:Grant-in-Aid for General Scientific Research (B)
-
资助金额:$4.29万
-
财政年份:1988
-
负责人:NAKAJIMA Katsuhisa
-
依托单位: